Optimi Completes First Commercial Shipment of GMP MDMA
First commercial shipment of GMP-certified MDMA capsules departs Princeton facility for a regulated access program partner.
PRINCETON, BC — Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF) today announced the first commercial shipment of its GMP-certified MDMA capsules to a regulated access program partner.
The shipment marks a transition from clinical-trial-grade supply to commercial supply, and follows the Company's Health Canada Controlled Drugs and Substances Dealer's Licence (DEL) amendment earlier this year.
"This is a meaningful milestone for the Company and for the regulated treatment programs we supply," said Dane Stevens, CEO. "It validates two years of manufacturing scale-up work at Princeton."